| Literature DB >> 31073385 |
Jessica Plácido1, José Vinicius Ferreira2, Felipe de Oliveira3, Paula Sant'Anna4, Renato Sobral Monteiro-Junior5, Jerson Laks6, Andrea C Deslandes7.
Abstract
Aerobic capacity declines significantly throughout life, beginning at the age of 30 years and accelerating from 60 years, where a decline of 17% per decade is expected thereafter.Entities:
Keywords: Alzheimer’s disease; aerobic capacity; cognitive function; mild cognitive impairment; physical function
Year: 2019 PMID: 31073385 PMCID: PMC6497027 DOI: 10.1590/1980-57642018dn13-010011
Source DB: PubMed Journal: Dement Neuropsychol ISSN: 1980-5764
Figure 1Flow chart of subject selection process.
Descriptive analyses of the samples.
| Healthy | MCI | Mild AD | Moderate AD | χ2/F | p | ||
|---|---|---|---|---|---|---|---|
| Age (years) | 74.2±9.2 | 78.0±5.5 | 78.5±7.4 | 78.9±8.3 | 2.041[ | 0.02 | |
| Education (years) | 12 (1-29) | 15 (3-18) | 11 (2-23) | 12 (1-16) | 6.025[ | 0.02 | |
| Sex (% of total cohort) | Female | 30 (31.9%) | 10 (11%) | 16 (17.6%) | 6 (6.6%) | 8.743[ | 0.03 |
| Male | 6 (6.6%) | 8 (8.8%) | 9 (8.8%) | 8 (8.8%) | |||
| Medication (n) | 2 (0-9) | 1 (0-7) | 5 (1-11) | 2.5 (1-9) | 14.731[ | 0.002 | |
| Chronic diseases (n) | 0.5 (1-3) | 1 (1-3) | 2 (1-6) | 0.5 (1-3) | 14.398[ | 0.002 | |
| Cardiovascular disease (n) | 0 (0-1) | 0.5 (0-2) | 0 (0-2) | 0 (0-1) | 7.502[ | 0.05 [ | |
| BMI (kg/m2) | 25.8 (20.9-34.0) | 25.1 (22.0-32.2) | 24.9 (18.7-38.2) | 25.6 (18.6-28.9) | 0.437[ | 0.93 | |
| VO2max (mL . kg-1.min-1) | 22.2±6.2 | 21.1±4.7 | 18.2±4.6 | 17.7±6.5 | 3.626[ | 0.01 | |
| STEP test (score) | 87.6±20.8 | 75.7±21.0 | 63.8±27.2 | 54.6±26.5 | 8.553[ | <0.001 | |
| IPAQ (METs/week) | 883.5 (33-12.558) | 1221.7 (50-6.384) | 462 (66-6.132) | 772.5 (132-1.448) | 7.382[ | 0.06 | |
| Lawton (score) | 21 (6-27) | 20 (11-21) | 13 (8-18) | 10 (7-17) | 59.286[ | <0.001 | |
| MMSE (score) | 29 (21-30) | 29 (19-30) | 21 (13-28) | 15 (5-22) | 59.040[ | <0.001 |
BMI: body mass index; MET: metabolic equivalent; MMSE: Mini-Mental State Examination; mean ± standard deviation; Median (minimum - maximum); χ2: chi-squared.
one-way ANOVA;
Kruskall-Wallis Test;
Significant difference among Healthy, mild AD and moderate AD;
Significant difference between Healthy and mild AD;
Significant difference between Healthy and MCI;
Significant difference among MCI, mild AD and moderate AD;
Significant difference between MCI and mild AD. Level of significance: p=0.05.
Association between aerobic capacity and the different diagnoses.
| Model | B | 95% CI | p | ||
|---|---|---|---|---|---|
|
| |||||
| 1 | Diagnosis | -11.2 | -15.6 | -6.9 | <0.001 |
|
| |||||
| 2 | Age | -0.5 | -1.1 | -0.04 | 0.03 |
| Sex | 22.6 | 13.4 | 31.8 | <0.001 | |
| Education | 0.6 | -0.1 | 1.4 | 0.09 | |
| Diagnosis | -12.0 | -16.0 | -8.0 | <0.001 | |
B: unstandardized coefficients. CI: confidence interval.
level of significance: p ≤0.005.
Association between Risk of Functional Loss (RFL) on STEP test and diagnosis of MCI and AD.
| MCI | Mild AD | Moderate AD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | (95% CI) | p | OR | (95% CI) | p | OR | (95% CI) | p | ||||
| STEP test | Without RFL | Reference | ||||||||||
| RFL | 3.0 | 0.76-11.71 | 0.11 | 7.6 | 2.22-26.20 | 0.001 | 8.0 | 1.93-33.10 | 0.004 | |||
| Without RFL | Reference | |||||||||||
| RFL | 4.5 | 0.99-21.10 | 0.05 | 10.7 | 2.65-43.64 | 0.001 | 14.7 | 2.63-82.11 | 0.002 | |||
OR: odds ratio; CI: confidence interval;
Adjusted for age, sex and educational level. Level of significance: p ≤0.05.